MA43331A - Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7 - Google Patents
Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7Info
- Publication number
- MA43331A MA43331A MA043331A MA43331A MA43331A MA 43331 A MA43331 A MA 43331A MA 043331 A MA043331 A MA 043331A MA 43331 A MA43331 A MA 43331A MA 43331 A MA43331 A MA 43331A
- Authority
- MA
- Morocco
- Prior art keywords
- smad7
- treatment
- methods
- oligonucleotide
- senses
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 101700026522 SMAD7 Proteins 0.000 title 1
- 102000049873 Smad7 Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462065598P | 2014-10-17 | 2014-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43331A true MA43331A (fr) | 2017-08-23 |
Family
ID=54330761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043331A MA43331A (fr) | 2014-10-17 | 2015-10-16 | Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10337004B2 (enExample) |
| EP (1) | EP3207136A1 (enExample) |
| JP (1) | JP2017532961A (enExample) |
| KR (1) | KR20170069262A (enExample) |
| CN (1) | CN107406851A (enExample) |
| AU (1) | AU2015332624A1 (enExample) |
| CA (1) | CA2964667A1 (enExample) |
| EA (1) | EA201790867A1 (enExample) |
| IL (1) | IL251717A0 (enExample) |
| MA (1) | MA43331A (enExample) |
| MX (1) | MX2017004973A (enExample) |
| WO (1) | WO2016059239A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| SI3121280T1 (sl) | 2008-11-13 | 2025-08-29 | Nogra Pharma Limited | Antismiselne sestave in postopki za njihovo izdelavo ter uporabo |
| JP6389122B2 (ja) | 2011-09-15 | 2018-09-12 | ノグラ ファーマ リミテッド | 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 |
| CN107252492A (zh) | 2012-04-18 | 2017-10-17 | 诺格尔制药有限公司 | 治疗糖尿病和/或促进胰岛移植后存活的方法 |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| CA2948411A1 (en) | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| JP2017537973A (ja) * | 2014-10-17 | 2017-12-21 | ノグラ ファーマ リミテッド | バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法 |
| KR20170069262A (ko) | 2014-10-17 | 2017-06-20 | 노그라 파마 리미티드 | Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물 |
| WO2017147276A1 (en) | 2016-02-23 | 2017-08-31 | Celgene Corporation | Methods of treating intestinal fibrosis using smad7 inhibition |
| JP2020503327A (ja) * | 2016-12-30 | 2020-01-30 | ノグラ ファーマ リミテッド | Ｓｍａｄ７アンチセンスオリゴヌクレオチドの組成物および乾癬を処置するまたは予防する方法 |
| IL296562A (en) * | 2020-04-24 | 2022-11-01 | Nogra Pharma Ltd | Compositions of smad7 antisense oligonucleotides (aso) and methods of using the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1456380E (pt) | 2001-11-02 | 2012-07-23 | Giuliani Int Ltd | Inibidores smad7 para o tratamento de doenças do snc |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| SI3121280T1 (sl) | 2008-11-13 | 2025-08-29 | Nogra Pharma Limited | Antismiselne sestave in postopki za njihovo izdelavo ter uporabo |
| WO2010085151A2 (en) * | 2009-01-26 | 2010-07-29 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil |
| WO2011097644A2 (en) * | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| JP6389122B2 (ja) | 2011-09-15 | 2018-09-12 | ノグラ ファーマ リミテッド | 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 |
| CN107252492A (zh) | 2012-04-18 | 2017-10-17 | 诺格尔制药有限公司 | 治疗糖尿病和/或促进胰岛移植后存活的方法 |
| MX363746B (es) | 2013-03-15 | 2019-04-01 | Nogra Pharma Ltd | Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal. |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| CA2948411A1 (en) * | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| WO2015011694A2 (en) | 2014-10-17 | 2015-01-29 | Celgene Corporation | Isotopologues of smad7 antisense oligonucleotides |
| KR20170069262A (ko) | 2014-10-17 | 2017-06-20 | 노그라 파마 리미티드 | Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물 |
| JP2017537973A (ja) | 2014-10-17 | 2017-12-21 | ノグラ ファーマ リミテッド | バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法 |
| MA41271A (fr) | 2014-12-26 | 2017-10-31 | Celgene Alpine Invest Company Ii Llc | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 |
| CA3000195A1 (en) | 2015-09-30 | 2017-04-06 | Celgene Alpine Investment Company Ii, Llc | Tlr modulators and methods of use |
| JP2018531936A (ja) | 2015-09-30 | 2018-11-01 | ノグラ ファーマ リミテッド | バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法 |
-
2015
- 2015-10-16 KR KR1020177012839A patent/KR20170069262A/ko not_active Withdrawn
- 2015-10-16 MX MX2017004973A patent/MX2017004973A/es unknown
- 2015-10-16 JP JP2017520449A patent/JP2017532961A/ja active Pending
- 2015-10-16 CA CA2964667A patent/CA2964667A1/en not_active Abandoned
- 2015-10-16 WO PCT/EP2015/074066 patent/WO2016059239A1/en not_active Ceased
- 2015-10-16 EP EP15781642.2A patent/EP3207136A1/en not_active Withdrawn
- 2015-10-16 CN CN201580069041.9A patent/CN107406851A/zh active Pending
- 2015-10-16 US US15/519,468 patent/US10337004B2/en not_active Expired - Fee Related
- 2015-10-16 EA EA201790867A patent/EA201790867A1/ru unknown
- 2015-10-16 MA MA043331A patent/MA43331A/fr unknown
- 2015-10-16 AU AU2015332624A patent/AU2015332624A1/en not_active Abandoned
-
2017
- 2017-04-13 IL IL251717A patent/IL251717A0/en unknown
-
2019
- 2019-05-21 US US16/418,108 patent/US20190338283A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170240893A1 (en) | 2017-08-24 |
| EP3207136A1 (en) | 2017-08-23 |
| IL251717A0 (en) | 2017-06-29 |
| CN107406851A (zh) | 2017-11-28 |
| JP2017532961A (ja) | 2017-11-09 |
| MX2017004973A (es) | 2017-12-07 |
| US10337004B2 (en) | 2019-07-02 |
| WO2016059239A1 (en) | 2016-04-21 |
| US20190338283A1 (en) | 2019-11-07 |
| CA2964667A1 (en) | 2016-04-21 |
| KR20170069262A (ko) | 2017-06-20 |
| AU2015332624A1 (en) | 2017-05-04 |
| EA201790867A1 (ru) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43331A (fr) | Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7 | |
| CY1121037T1 (el) | Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
| JOP20200115A1 (ar) | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) | |
| IL271446A (en) | Compositions and methods for chemical cleavage and deprotection of surface-bound oligonucleotides | |
| MX2017008183A (es) | Nucleosidos sustituidos, nucleotidos y analogos de estos. | |
| EA201692537A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| EA201692370A1 (ru) | КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| HK1224229A1 (zh) | 取代的核苷，核苷酸及其类似物 | |
| CU24574B1 (es) | Oligonucleótido que contiene una secuencia nucleobase para disminuir la expresión de tau | |
| MX2017011013A (es) | Terapia de oligonucleotidos para amaurosis congenita de leber. | |
| DK3265102T3 (da) | Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituerede-2-modificerede-n6-substituerede purinnukleotider til hcv-behandling | |
| MD4760B1 (ro) | Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D | |
| TR201818825T4 (tr) | Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar | |
| MA44836A (fr) | Procédés de traitement du syndrome polykystique des reins | |
| WO2017055611A3 (en) | Methods of using smad7 antisense oligonucleotides based on biomarker expression | |
| MA39885A (fr) | Procédés de caractérisation et de traitement de la leucémie myéloïde aiguë | |
| EP3353332A4 (en) | SELECTIVE REMOVAL OF PRECIOUS METALS WITH ACID LIQUIDS, INCLUDING LIQUIDS WITH NITRATIONS | |
| EA201890379A1 (ru) | Терапевтические олигонуклеотиды | |
| MY203259A (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| EA201791986A1 (ru) | Олигонуклеотиды, соответствующие экзону 73 гена col7a1, для терапии буллезного эпидермолиза | |
| NZ738100A (en) | Igfbp3 and uses thereof | |
| MX2017013749A (es) | Composiciones y metodos para construir genotecas de adnc especificas de hebra. | |
| EA201791471A1 (ru) | Способы применения антисмысловых олигонуклеотидов smad7 | |
| WO2016050835A3 (en) | Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component | |
| ES2671745T3 (es) | Detección de Neisseria gonorrhoeae |